Karolinska Development (publ) announced that one of its portfolio companies, Dilafor AB, has concluded an extensive clinical study of its candidate drug, tafoxiparin, a new drug substance for the prevention of protracted labor during childbirth. The promising results of the Phase II trial bring the project closer to exit in line with Karolinska Development's business strategy.
« previous1 next »
The only healthy natural way to shop garlic is the Moroccan brass kitchen...
There’s an interesting post over at the Health Journal Club that makes...
Nice that a very interesting topic which you provide in this site about...
Savings rates going down seems to be like a reoccurring trend every year...
That is worrying enough for our body, because if the secret is hidden in...
Disscusion boards licensed and powered by ZoneX v3.3.1 Development supported by LifeForm Inc.
All Rights Reserved by SteadyHealth.com
© 2004 - 2009
This site complies with the HONcode standard for trustworthy health information:
verify here.
